# US 10,117,676 B2 · Method of embryo transfer that eliminates transferred air while hormonally inducing implantation and apparatus

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,117,676 B2
- Document ID: US10117676B2
- Status: Granted
- Kind: B2
- Application number: 14/797,411
- Filed: 2015-07-13
- Published: 2015-11-05
- Granted: 2018-11-06
- Earliest claimed: 2008-08-06
- Assignees: Incintas Therapeutics, Inc.
- Applicants: Incintas Therapeutics, Inc.
- Inventors: Jesse Albert Pizolato
- Web page: https://patentgrep.com/patent/US10117676B2

## CPC

- A61B 17/435: for embryo {or ova} transplantation
- A61B 17/00234: {for minimally invasive surgery (A61B17/0218, A61B17/0469, A61B17/12013, A61B17/1285, A61B17/29, A61B17/320016 take precedence)}
- A61K 31/565: not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K 31/57: substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61M 25/00: Catheters; Hollow probes (dilators A61M29/00; {peritoneal catheters A61M1/285; tracheal tubes A61M16/04; for drainage A61M27/00; for uterus, vagina or rectum A61M31/00} ; for measuring or testing A61B; {materials for catheters A61L29/00})
- A61M 25/0067: {characterised by the distal end, e.g. tips (A61M25/0054, A61M25/04 take precedence; balloon catheters A61M25/10)}
- A61P 15/18: Feminine contraceptives
- A61B 2017/00292: {mounted on or guided by flexible, e.g. catheter-like, means}
- A61B 2090/063: {for measuring volume}
- A61B 2090/0807: {Indication means}
- A61M 2025/0008: {having visible markings on its surface, i.e. visible to the naked eye, for any purpose, e.g. insertion depth markers, rotational markers or identification of type}
- A61M 2210/1433: Uterus
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61M: DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY (introducing media into or onto the bodies of animals A61D7/00; means for inserting tampons A61F13/26; devices for administering food or medicines orally A61J; containers for collecting, storing or administering blood or medical fluids A61J1/05); DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY (surgery A61B; chemical aspects of surgical articles A61L); DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR {(Electrotherapy, e.g. producing anaesthesia by the use of alternating or intermittent currents A61N1/36021)}
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A method of embryo transfer (“ET”) that improves fertility rates by eliminating transferred air during the procedure is provided. Also provided is a method for hormonally enhancing the uterine wall of a patient either prior to or during the time of ET. Quantitative administration of transfer solutions is accomplished with a modified apparatus that provides for implantation of an embryo into the uterus of a patient. The apparatus comprises an outer sheath and an inner lumen arranged to be slidably disposed within the outer sheath. The inner lumen includes at least one visual marker situated on the exterior surface adjacent its distal end thereof.

## Claims

### Claim 1

A method for artificial embryonic implantation in a uterine wall of a female subject comprising:
a. directly administering at least one implantation promoter in a nanoformulation sufficient to promote an activation of uterine factors at a target site on the uterine wall within a window of implantation; and
b. depositing a fertilized embryo at a prepared site
wherein administering the implantation promoter and depositing a fertilized embryo are through a distal end of an inner lumen for an embryo transfer delivery catheter to locally target a portion of the uterine wall.

### Claim 2 (depends on 1)

The method of claim 1 wherein the female subject is human.

### Claim 3 (depends on 1)

The method of claim 1 wherein the implantation promoter is selected from a group consisting of known amounts of progesterone, estrogen, and a combination thereof.

### Claim 4 (depends on 1)

The method of claim 1 wherein the implantation promoter is progesterone.

### Claim 5 (depends on 1)

The method of claim 1 wherein a concentration of the implantation promoter is between approximately 0.001 micrograms to 1000 milligrams administered at the target site.

### Claim 6 (depends on 1)

The method of claim 1 wherein the uterine factors are selected from the group consisting of aquaporins, epithelial sodium channels, prostaglandins, activation of a sodium pump, HNE-1 protein and combinations thereof.

### Claim 7 (depends on 1)

The method of claim 1 wherein the window of implantation is a time period for having a maximum effect on the uterine factors as determined at the target site for an individual female subject.

### Claim 8 (depends on 1)

The method of claim 1 wherein the window of implantation is between approximately a day of depositing a fertilized embryo to approximately 270 days prior to depositing a fertilized embryo.

### Claim 9 (depends on 1)

The method of claim 1 wherein administering the implantation promoter through the embryo transfer delivery catheter is prior to the delivery of the fertilized embryo.